A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor

64Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Antibodies have brought valuable therapeutics in the clinical treatment of various diseases without serious adverse effects through their intrinsic features such as specific binding to the target antigen with high affinity, clinical safety as serum proteins, and long half-life. Agonist antibodies, furthermore, could be expected to maximize the value of therapeutic antibodies. Indeed, several IgG/IgM antibodies have been reported to induce cellular growth/differentiation and apoptosis. These agonist antibodies, however, should be further improved to exert more potent biologic activities and appropriate serum half-life depending upon the disease indications. Here, we report that IgG antibodies against the thrombopoietin receptor (Mpl), which have an absence or very weak agonist activity, can be engineered to be agonist minibodies, which include diabody or sc(Fv)2 as potent as natural ligand. Through this technological development, minibodies have been successfully constructed to bind and activate 2 types of dysfunctional mutant Mpls that cause congenital amegakaryocytic thrombocytopenia (CAMT). This drastic conversion of biologic activities by designing minibodies can be widely applicable to generate agonist minibodies for clinical application, which will constitute a new paradigm in antibody-based therapeutics. © 2005 by The American Society of Hematology.

Figures

References Powered by Scopus

Efficient selection for high-expression transfectants with a novel eukaryotic vector

4783Citations
N/AReaders
Get full text

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

1482Citations
N/AReaders
Get full text

Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand

1266Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Next generation antibody drugs: Pursuit of the 'high-hanging fruit'

600Citations
N/AReaders
Get full text

New thrombopoietic growth factors

308Citations
N/AReaders
Get full text

Megakaryocyte development and platelet production

257Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Orita, T., Tsunoda, H., Yabuta, N., Nakano, K., Yoshino, T., Hirata, Y., … Tsuchiya, M. (2005). A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood, 105(2), 562–566. https://doi.org/10.1182/blood-2004-04-1482

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘20‘22‘23‘2401234

Readers' Seniority

Tooltip

Researcher 4

36%

Professor / Associate Prof. 3

27%

PhD / Post grad / Masters / Doc 3

27%

Lecturer / Post doc 1

9%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 4

36%

Biochemistry, Genetics and Molecular Bi... 3

27%

Medicine and Dentistry 2

18%

Pharmacology, Toxicology and Pharmaceut... 2

18%

Save time finding and organizing research with Mendeley

Sign up for free
0